Home  »  Companies   »  Here are the top Institutional holders of Coherus ...

Here are the top Institutional holders of Coherus BioSciences Inc. (CHRS) shares

Coherus BioSciences Inc. (NASDAQ: CHRS) is -58.96% lower on its value in year-to-date trading and has touched a low of $5.60 and a high of $19.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CHRS stock was last observed hovering at around $6.55 in the last trading session, with the day’s loss setting it 0.0% off its average median price target of $15.00 for the next 12 months. It is also 78.17% off the consensus price target high of $30.00 offered by 8 analysts, but current levels are 40.45% higher than the price target low of $11.00 for the same period.

Currently trading at $6.55, the stock is -15.90% and -23.86% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.5 million and changing 0.00% at the moment leaves the stock -32.70% off its SMA200. CHRS registered -65.14% loss for a year compared to 6-month gain of -11.61%.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

The stock witnessed a -23.66% loss in the last 1 month and extending the period to 3 months gives it a -48.99%, and is -10.88% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.86% over the week and 6.66% over the month.

Coherus BioSciences Inc. (CHRS) has around 376 employees, a market worth around $507.17M and $239.10M in sales. Distance from 52-week low is 16.96% and -65.53% from its 52-week high. The company has generated returns on investments over the last 12 months (-52.00%).

Coherus BioSciences Inc. (CHRS) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Coherus BioSciences Inc. (CHRS) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.40, where 3 rate it as a Hold and 1 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

The EPS is expected to shrink by -334.40% this year

Coherus BioSciences Inc. (CHRS) Top Institutional Holders

The shares outstanding are 77.75M, and float is at 71.61M with Short Float at 13.01%.

Coherus BioSciences Inc. (CHRS): Who are the competitors?

The company’s main competitors (and peers) include Affimed N.V. (AFMD) that is trading -69.02% down over the past 12 months and Acorda Therapeutics Inc. (ACOR) that is -80.51% lower over the same period. Repligen Corporation (RGEN) is -36.04% down on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam

111365

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.